| CASE REPORT |
|
| Year : 2023 | Volume
: 15
| Issue : 1 | Page : 39-40 |
|
|
Mesotherapy with bicalutamide: A new treatment for androgenetic alopecia
Alba Gomez-Zubiaur1, Juan Jose Andres-Lencina1, Víctor Cabezas1, Cristina Corredera1, Fabio di Brisco2, Blanca Ferrer1, Ana Rodriguez-Villa1, Daniela Subiabre-Ferrer1, Cristian Valenzuela1, David Vega Diez1, Jose Maria Ricart1
1 Trichology Unit, Ricart Medical Institute, Madrid and Valencia, Spain
2 Pharmacy Unit, Ricart Medical Institute, Madrid and Valencia, Spain
Correspondence Address:
Alba Gomez-Zubiaur
Trichology Unit, Ricart Medical Institute, Paseo de la Habana 43, 28036 Madrid
Spain
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_78_21
|
|
|
Bicalutamide is a selective androgen receptor antagonist. To date, it has been used orally with good efficacy results, but not in mesotherapy. In our center, we assessed whether patients undergoing bicalutamide mesotherapy showed positive responses and tolerated the local administration of bicalutamide. Six premenopausal women, with a mean age of 35.7 years and clinical diagnosis of Olsen Grade II or III female androgenetic alopecia accompanied by significant seborrhea were treated with 1 ml bicalutamide 0.5% mesotherapy. Three monthly sessions were performed. A subtle improvement in hair density was described after the third session. The overall satisfaction of the patients with the treatment was 6.3, on a scale of 1–10. Premenopausal women require several therapeutic approaches to combat severe androgenetic alopecia. Our data showed that bicalutamide mesotherapy was well tolerated and welcomed by the patients; we, therefore, provide a new tool for the management of this pathology.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
